Answers are grounded in this paper and cite their sources.
Biomimetic nanocarriers improve drug delivery in neurological disorders, suggesting pathways for clinical applications.
Biomimetic nanocarriers offer a promising strategy to overcome biological barriers and improve central nervous system drug delivery. However, clinical translation remains challenged by membrane source standardization, scalability, and safety concerns. Future research should focus on reproducible manufacturing, regulatory frameworks, and long-term toxicity evaluation to accelerate clinical adoption.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: